AMGN

Amgen Becomes Oversold

The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals and a valuation that looks inexpensive. Amgen Inc (Symbol: AMGN) presently has an excellent rank, in the top 25% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors.

But making Amgen Inc an even more interesting and timely stock to look at, is the fact that in trading on Friday, shares of AMGN entered into oversold territory, changing hands as low as $271.48 per share. We define oversold territory using the Relative Strength Index, or RSI, which is a technical analysis indicator used to measure momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30. In the case of Amgen Inc, the RSI reading has hit 29.4 — by comparison, the universe of dividend stocks covered by Dividend Channel currently has an average RSI of 52.5. A falling stock price — all else being equal — creates a better opportunity for dividend investors to capture a higher yield. Indeed, AMGN's recent annualized dividend of 9/share (currently paid in quarterly installments) works out to an annual yield of 3.28% based upon the recent $274.33 share price.

A bullish investor could look at AMGN's 29.4 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. Among the fundamental datapoints dividend investors should investigate to decide if they are bullish on AMGN is its dividend history. In general, dividends are not always predictable; but, looking at the history chart below can help in judging whether the most recent dividend is likely to continue.

AMGN+Dividend+History+Chart

Click here to find out what 9 other oversold dividend stocks you need to know about »

Also see:
• Joel Greenblatt Stock Picks
• Stryker MACD
• WERN Insider Buying

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Info icon

This data feed is not available at this time.

Data is currently not available

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.